Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris volutpat odio sed quam porttitor, et scelerisque quam ornare. Donec eu maximus diam. Sed nec nulla quis magna sagittis laoreet ac in ligula.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris volutpat odio sed quam porttitor, et scelerisque quam ornare. Donec eu maximus diam. Sed nec nulla quis magna sagittis laoreet ac in ligula.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris volutpat odio sed quam porttitor, et scelerisque quam ornare. Donec eu maximus diam. Sed nec nulla quis magna sagittis laoreet ac in ligula.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris volutpat odio sed quam porttitor, et scelerisque quam ornare. Donec eu maximus diam. Sed nec nulla quis magna sagittis laoreet ac in ligula.

Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.